Nohla Therapeutics, Inc.

Venture capital investment in biopharmaceutical companies totaled $9.7bn in the first half of this year, so if the pace of $4.8bn per quarter keeps up, 2018 will beat the $12.4bn invested in private d

The progression of investigational products through a series of increasingly sophisticated and targeted clinical trials is a well-tried and tested route for the development of new medicines for commer

Derived from Strategic Transactions , Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biophar

George Golumbeski, who ran Celgene Corp. 's business development group during an active period of deal-making there, has left the big biotech to hang his own shingle as a life science business consul